From off-the-shelf to custom: how modern assay development accelerates biotech innovation
Most early biotech companies follow the same basic trajectory in assay development. There is a novel biology problem and a funding milestone to make or break. The first instinct for most people is to grab an off-the-shelf assay. They are validated, there is a protocol included, and you get a lot of data really quickly from a small lab in days. When there is a well-defined biology and a known readout, off-the-shelf is often the right choice.
Where off-the-shelf assays reach their limits
The limitations become obvious the moment you add biological complexity. Commercial kits are developed with a certain model in mind. Antibodies raised against a canonical antigen will likely cross-react in your particular cell line. Viability reagents will function differently in primary cells compared to immortalised cells. Reporter assays optimised for one signalling pathway cannot necessarily detect the mechanism that no one has targeted before. When the readout you need is not a catalogue item, or the available option gives a signal window too narrow to trust, off-the-shelf stops being the efficient option.
A biology that requires a custom readout
Custom assay development comes into play when the biology outpaces the catalogue which is often the case for the more innovative biotechs. Creating a readout based on the specific scientific problem allows achieving better validation and more credible proof-of-concept data. It actually reflects the biology that you need to study rather than a proxy for it.
Weighing the benefits of developing a custom assay
It is a balance of science and business. The scientific issues: is there an antibody or probe that works, what the dynamic range would be, and how you can distinguish hits from background noise. Metrics like Z-factor or inter-assay coefficient of variation tell you whether your readout is robust enough to use as a decision point.
From the business perspective, the trade-off is cost and time now versus cost and risk later. It is more time-consuming to develop a custom assay. But a weak assay used in a screening run will lead to false positives, dead ends and wasted money.
Optimisation and validation
Most of the heavy lifting is done during optimisation, and the process usually requires adaptation. Conditions like cell model, buffer conditions, incubation time and control must be optimised. You will have to consider reagent batch variations, edge effects, and signal drift over long experiments. The goal is to get a robust readout that gives you consistent results.
This is what defines your assay. Reproducibility, sensitivity and specificity determine whether your go/no-go decision is sound. An assay that targets your biological readout without cross-reacting with something else, detects any changes in the target at a relevant concentration, and scales to higher throughput screens decreases technical risks before your company starts expensive pre-clinical studies.
Why does the quality of data matter for funding decisions
Assay strategy also affects how your company is evaluated by those who invest in it. For investors, grant reviewers, and other accelerator scientists, the quality of data is a marker of rigorous science. A fit-for-purpose assay shows that the biology was studied rather than assumed. This is a big part of Discovery Studio’s work with early-stage companies: assay development aimed to answer the right question, withstand scrutiny, and deliver data that can be used by the founders.
FAQs:
1. When should a team opt for off-the-shelf assays or decide to develop a custom assay?
Go with commercial kits for well-studied targets with known readouts and tight timelines. Develop a custom assay if your biology is novel, there isn’t a reagent to validate the biology, or the signal window is too narrow to trust.
2. What are the key steps to transition an off-the-shelf assay into a validated custom readout for novel targets?
Identify a biological question. Choose a cell model and a set of controls. Optimise conditions to increase the signal window. Validate the assay for reproducibility, sensitivity, and specificity and then scale to the desired format.
3. How do cost, time, and scalability compare between off-the-shelf and custom assay strategies in accelerator settings?
Off-the-shelf assays are cheap and quick to start with, but they won’t scale to novel targets. Custom assays are more costly and time-consuming at the start, but they are much more scalable and prevent mistakes down the road.